Abstract
Purpose :
To investigate whether IWOS criteria-diagnosed ocular sarcoidosis differs from idiopathic uveitis with similar ocular manifestations with respect to demographics, clinical course, and visual outcomes.
Methods :
“IWOS criteria-diagnosed ocular sarcoidosis” was defined as uveitis with features meeting the International Workshop on Ocular Sarcoidosis (IWOS) criteria, and “suspected ocular sarcoidosis” was defined as idiopathic uveitis with at least 3 of 7 IWOS ocular clinical signs suggestive of but not meeting the IWOS criteria for ocular sarcoidosis. Clinical records were retrospectively reviewed of 107 patients (210 eyes with uveitis) with IWOS criteria-diagnosed ocular sarcoidosis (OS group) and 37 patients (73 eyes with uveitis) with suspected ocular sarcoidosis (SS group) presenting between 2011 and 2018 to the Kyorin Eye Center.
Results :
The mean age at presentation was 60 years for the OS group and 59 years for the SS group. The percentage of women was 71% for the OS group and 78% for the SS group. The anatomic type of uveitis was panuveitis in 85% and 97% of patients in the OS and SS groups, respectively. The mean follow-up period was significantly longer for the OS group (48 months) compared to that for the SS group (29 months). Laboratory work-up demonstrated that both the serum levels of angiotensin converting enzyme and soluble interleukin-2 receptor were significantly higher for the OS group. There was no significant difference in rate of ocular complications including cataract, glaucoma, and macular edema between the 2 groups. Furthermore, the percentage of patients receiving systemic corticosteroid therapy or sub-Tenon triamcinolone injections was comparable in the 2 groups. There was no significant difference in percentage of eyes with a best-corrected visual acuity of greater than or equal to 1.0 between the 2 groups at 1 and 3 years after presentation.
Conclusions :
No significant difference could be identified between IWOS-criteria diagnosed ocular sarcoidosis and suspected ocular sarcoidosis in terms of patient demographics, clinical course and visual outcomes.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.